FASgen and Tetracore sign collaborative agreement

The tests measure the over-expression of the enzyme fatty acid synthase (FAS), which is found in virtually all solid tumor cancers. FASgen’s FAS-detect Elisa and FAS-detect IHC tests, currently available for research purposes, have demonstrated repeated and highly significant success in identifying the progression of the disease in a series of different solid tumors, including, pancreas, ovarian, prostate and lung cancer.

FASgen Diagnostics and Tetracore have been working together for the last six years and the current transaction expands the antibody and kit production role to Tetracore’s FDA approved GMP production facility. Tetracore has also been given the opportunity to invest in FASgen Diagnostics.

William Nelson, president of Tetracore, said: “We welcome the opportunity to expand our working relationship with the FASgen Diagnostics team, and are very pleased that they were willing to select Tetracore as the first outside corporate investor to participate in their company.”